Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2011. The filing identifies the registrant as Capstone Therapeutics Corp., formerly OrthoLogic Corp.; the provided metadata refers to Capstone Holding Corp. The company is a development-stage biotechnology company focused on AZX100 and Chrysalin (TP508).
Business Context and Reporting Period
- AZX100 development included completed Phase 2 studies in keloid scar revision and dermal scarring following shoulder surgery; results from the latter study were reported in April 2011.
- Chrysalin development and vascular partnering efforts continued, but no clinical studies were planned for Chrysalin during 2011.
- The company was pursuing development, licensing, and partnering opportunities rather than advancing an active broad clinical program.
- As of October 31, 2011, 40,775,411 common shares were outstanding.
Financial Condition and Results
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | No revenue reported or disclosed | No revenue reported or disclosed |
| General and administrative expense | $391,000 in 2011; $698,000 in 2010 | $2.354 million in 2011; $2.460 million in 2010 |
| Research and development expense | $1.226 million in 2011; $1.911 million in 2010 | $4.684 million in 2011; $6.094 million in 2010 |
| Total operating expenses | $1.617 million in 2011; $2.609 million in 2010 | $7.038 million in 2011; $8.554 million in 2010 |
| Interest and other income, net | $2,000 in 2011; $28,000 in 2010 | $16,000 in 2011; $99,000 in 2010 |
| Net loss | $1.615 million, or $0.04 per share, in 2011; $2.581 million, or $0.06 per share, in 2010 | $7.022 million, or $0.17 per share, in 2011; $8.455 million, or $0.21 per share, in 2010 |
| Operating cash flow | Not separately disclosed | $(6.760) million in 2011; $(7.922) million in 2010 |
- At September 30, 2011, cash and cash equivalents were $17.608 million, down from $24.387 million at December 31, 2010.
- Total assets were $18.004 million, compared with $25.288 million at December 31, 2010.
- Total current liabilities were $764,000, compared with $1.816 million at year-end 2010.
- The filing does not report outstanding debt; liabilities consisted primarily of accounts payable and accrued obligations.
- Stockholders’ equity was $17.240 million at September 30, 2011, compared with $7.916 million at December 31, 2010. The prior-year balance included $15.556 million of potentially redeemable equity related to shareholder put rights.
- Accumulated deficit was $171.828 million, including approximately $144 million of net losses incurred during the development-stage period.
Material Changes Versus Prior Comparable Period
- Third-quarter net loss declined by approximately $1.0 million, primarily because of lower clinical expenses and elimination of the performance-based bonus plan.
- Nine-month net loss declined by approximately $1.4 million, driven mainly by reduced Phase 2 clinical costs and lower incentive compensation, partly offset by higher internal research, peptide acquisition, investor-relations, and business-development costs.
- Research and development spending fell 36% year over year for the quarter and 23% for the nine-month period, principally because major Phase 2 activities were completed or substantially completed in 2010.
- Cash declined by $6.779 million during the first nine months of 2011, compared with a $1.181 million decline in the comparable 2010 period.
- Shareholder put rights expired on June 30, 2011 after the board determined that the company could not purchase shares under the applicable conditions. The related potentially redeemable equity was reduced to zero.
- The common stock was delisted from the Nasdaq Capital Market effective July 21, 2011 and subsequently traded on OTC quotation systems.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that September 30, 2011 cash and cash equivalents were expected to fund presently projected cash and working-capital requirements for the next year.
- Additional capital would be required to complete clinical trials and supporting research and manufacturing necessary for potential FDA approval. Possible funding sources include debt or equity financing, joint development, asset sales, and licensing transactions, none of which were assured.
- On October 13, 2011, the board adopted a cash-preservation plan reducing full-time employees from 18 to four. Several executives became consultants, compensation was substantially reduced, and the bonus plan was cancelled.
- Authorized severance totaled approximately $1.7 million, most of which was expected to be paid in the fourth quarter of 2011; no severance was accrued at September 30, 2011.
- The workforce reduction may limit development progress, delay partnering activities, and make it difficult to restore prior operating capacity.
- A pending qui tam lawsuit relating to the former bone-device business seeks civil penalties and potentially treble damages that could exceed the company’s financial resources. Management believes the ultimate resolution will not materially affect the company, but acknowledges that an unfavorable outcome could materially impair liquidity and continuation of operations.
- Delisting and penny-stock regulations may reduce trading liquidity, adversely affect the stock price, and impair future capital-raising capability.
- The filing states that disclosure controls were effective and that no material changes occurred in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the registrant’s legal name and identity because the filing names Capstone Therapeutics Corp., while the request metadata names Capstone Holding Corp.
- Assess cash runway after including approximately $1.7 million of fourth-quarter severance and ongoing operating cash burn.
- Monitor whether AZX100 or Chrysalin obtains a partner, licensee, or other funding source.
- Evaluate the potential financial exposure and litigation status of the qui tam proceeding.
- Verify the post-delisting trading venue, quotation continuity, liquidity, and penny-stock restrictions.
- Determine whether the company can resume clinical or development activities with its reduced workforce and without additional capital.